These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 11585753

  • 1. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
    Moasser MM, Basso A, Averbuch SD, Rosen N.
    Cancer Res; 2001 Oct 01; 61(19):7184-8. PubMed ID: 11585753
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 15; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 4. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M.
    Cancer Res; 2005 May 15; 65(10):4253-60. PubMed ID: 15899817
    [Abstract] [Full Text] [Related]

  • 5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 6. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB, Solit D, Basso A, Moasser MM.
    Clin Cancer Res; 2003 Oct 01; 9(12):4340-6. PubMed ID: 14555504
    [Abstract] [Full Text] [Related]

  • 7. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.
    Cancer Res; 2002 Jul 15; 62(14):4132-41. PubMed ID: 12124352
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
    Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):528-36. PubMed ID: 16965995
    [Abstract] [Full Text] [Related]

  • 9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 10. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 11. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 12. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Nakamura H, Takamori S, Fujii T, Ono M, Yamana H, Kuwano M, Shirouzu K.
    Cancer Lett; 2005 Dec 08; 230(1):33-46. PubMed ID: 16253759
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 15. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM.
    Melanoma Res; 2009 Jun 01; 19(3):156-66. PubMed ID: 19434003
    [Abstract] [Full Text] [Related]

  • 16. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T.
    FEBS Lett; 2005 Aug 01; 579(19):4069-75. PubMed ID: 16023108
    [Abstract] [Full Text] [Related]

  • 17. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 18. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A.
    J Cell Physiol; 2003 Apr 01; 195(1):139-50. PubMed ID: 12599217
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Oct 01; 8(10):3250-8. PubMed ID: 12374696
    [Abstract] [Full Text] [Related]

  • 20. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, Bundred NJ.
    Cancer Res; 2002 Jan 01; 62(1):122-8. PubMed ID: 11782368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.